US Pat. No. 11,111,537

METHODS OF DETECTING AUTOIMMUNE OR IMMUNE-RELATED DISEASES OR CONDITIONS

PRESIDENT AND FELLOWS OF ...


1. An assay for detecting a marker of an autoimmune or immune-related disease or condition in a human subject, wherein the autoimmune or immune-related disease or condition is multiple sclerosis or inflammatory bowel disease, the assay comprising:a) obtaining a macrophage having a DNA content of more than 2n (>2n macrophage cell) from the blood of the human subject, wherein the >2n macrophage has been separated from phagocytic cells having a DNA content of 2n (=2n phagocytic cells), and detecting a first gene expression profile of the marker of an autoimmune or immune-related disease or condition; and
b) obtaining a non-phagocytic cell from the blood of the human subject and detecting a second gene expression profile of the marker of an autoimmune or immune-related disease or condition in the obtained non-phagocytic cell.

US Pat. No. 11,111,282

COMPOSITIONS AND METHODS FOR VASCULAR PROTECTION AGAINST REPERFUSION INJURY AFTER MYOCARDIAL ISCHEMIA

THE UNIVERSITY OF VERMONT...


1. A method for reducing vascular endothelial cell damage or vascular endothelial cell death following myocardial ischemia with reperfusion in a subject, the method comprising administering to the subject intra-arterially a composition comprising an HGF/IgG complex at the time of reperfusion, wherein the HGF/IgG complex does not comprise an antibody-antigen interaction, thereby reducing vascular endothelial cell damage or vascular endothelial cell death following myocardial ischemia with reperfusion relative to a reference.
US Pat. No. 11,111,283

PEPTIDES AND COMPOSITIONS FOR TREATMENT OF JOINT DAMAGE

NOVARTIS AG, Basel (CH)


1. An isolated polynucleotide encoding a polypeptide having at least 95% amino acid sequence identity to a polypeptide consisting of the amino acid sequence set forth as SEQ ID NO: 28, wherein the polypeptide comprises an amino acid that is a polar amino acid other than K or R at position 423 as determined with reference to SEQ ID NO:1, and wherein the polypeptide has chondrogenic activity.
US Pat. No. 11,111,539

IDENTIFICATION OF PEDIATRIC ONSET INFLAMMATORY BOWEL DISEASE LOCI AND METHODS FOR USE THEREOF FOR THE DIAGNOSIS AND TREATMENT OF THE SAME


1. A method for treating inflammatory bowel disease (IBD) comprising detecting the presence of at least one IBD-associated single nucleotide polymorphism (SNP) in a target polynucleotide comprising:(a) isolating nucleic acids from a biological sample from a subject;
(b) detecting in the nucleic acids the presence of at least one IBD-associated-SNP selected from a Tat rs2315008 in the TNFRSF6B gene, an A at rs4809330 on chromosome 20 in the TNFRSF6B gene, and an A at rs2836878 on chromosome 21; and diagnosing the subject as having IBD or an increased risk of IBD based on the presence of the detected IBD-associated-SNP; and
(c) administering to the subject a therapeutically effective amount of a therapy useful for treating IBD.

US Pat. No. 11,114,123

MAGNETIC TAPE HAVING CHARACTERIZED MAGNETIC LAYER AND MAGNETIC RECORDING AND REPRODUCING DEVICE

FUJIFILM Corporation, To...


1. A magnetic tape comprising:a non-magnetic support; and
a magnetic layer including ferromagnetic powder and a binding agent on the non-magnetic support,
wherein the magnetic layer includes one or more components selected from the group consisting of fatty acid and fatty acid amide,
the C—H derived C concentration calculated from the C—H peak area ratio of C1s spectra obtained by X-ray photoelectron spectroscopic analysis performed on a surface of the magnetic layer at a photoelectron take-off angle of 10 degrees is equal to or greater than 45 atom %, and
the absolute value ?N of the difference between the refractive index Nxy measured regarding an in-plane direction of the magnetic layer and the refractive index Nz measured regarding a thickness direction of the magnetic layer is 0.25 to 0.40.

US Pat. No. 11,111,284

TUMOR NECROSIS FACTOR SUPERFAMILY AND TNF-LIKE LIGAND MUTEINS AND METHODS OF PREPARING

The General Hospital Corp...


1. A trimer comprising monomers of a soluble polypeptide, wherein said soluble polypeptide comprises a tumor necrosis factor superfamily (TNFSF) ligand or TNF-like ligand, or an extracellular domain thereof, wherein at least a first said soluble polypeptide of the trimer comprises an amino acid substitution or insertion that introduces a surface-exposed, exterior-facing cysteine residue at a position in the first soluble polypeptide that is located at a natural interface between monomers of the trimer, wherein an alpha carbon (C?) of the cysteine residue of the first soluble polypeptide is within 9 ? of a C? of a cysteine residue of a second said soluble polypeptide of the trimer that is also located at the natural interface between the monomers of the trimer, wherein the cysteine residue of the first soluble polypeptide is disulfide bonded to the cysteine residue of the second soluble polypeptide, and wherein said TNFSF or TNF-like ligand is tumor necrosis factor-? (TNF-?), lymphotoxin-? (LT-?), lymphotoxin-? (LT-?), cluster of differentiation 40 ligand (CD40L), cluster of differentiation 70 (CD70), receptor activator of nuclear factor kappa beta ligand (RANKL), tumor necrosis family receptor superfamily member 4 ligand (OX40L), cluster of differentiation 95 ligand (FasL), tumor necrosis family receptor superfamily member 9 (4-1BB ligand), TNF-related apoptosis-inducing ligand (TRAIL), TNF-related weak inducer of apoptosis (TWEAK), a proliferation-inducing ligand (APRIL), B lymphocyte stimulator (BLys), tumor necrosis family receptor superfamily member 14 (LIGHT), TNF-like ligand 1 (TL1), glucocorticoid-induced TNF receptor ligand (GITRL), ectodysplasin A1 (EDA-A1), ectodysplasin A2 (EDA-A2), or adiponectin.
US Pat. No. 11,111,540

ASSESSMENT OF RISK OF ANEUPLOIDY

BLUEGNOME LTD, Cambridge...


1. A system for selecting a human egg for transfer in an in vitro fertility procedure, the human egg comprising a first polar body (PB1), the first polar body comprising one or more PB1 chromosomes, the system comprising:an oligonucleotide microarray configured to perform a nucleic acid detection assay to interrogate genotype data of at least 25 biallelic SNPs flanking the centromeres of said one or more PB1 chromosomes, said SNPs in a region located within 5 to 10 Mb of the centromere, and
a computer readable medium having stored thereon non-transitory computer-readable instructions for:
a) accessing a database comprising genotype data obtained from said microarray,
b) quantifying said biallelic SNPs that are heterozygous relative to a total number of SNPs in the region, to obtain a proportion of heterozygous SNPs,
c) comparing the proportion of heterozygous SNPs to one or more threshold values associated with high levels of centromeric heterozygosity; and
d) classifying the one or more PB1 chromosomes as having (i) a high degree of centromeric heterozyosity (CH) or (ii) a low degree of centromeric heterozygosity, based on the comparison of the proportion of heterozygous SNPs to the one or more threshold values; and
e) outputting, to a display device. instructions to selectively transfer said human egg ahead of other eggs when said human egg is classified as having a low degree of centromeric heterozygosity.

US Pat. No. 11,111,285

GLUCAGON-GLP-1-GIP TRIPLE AGONIST COMPOUNDS


1. A glucagon-GLP-1-GIP triple agonist compound having the general formula:R1-Y-Aib-QGTFTSDYSIYLDK-K([17-carboxy-heptadecanoyl]-isoGlu)-AQRAFVEWLLAQGPSSGAPPPS-R2 (SEQ ID NO: 33)
wherein
R1 is H—, C1-4 alkyl, acetyl, formyl, benzoyl, trifluoroacetyl or pGlu;
R2 is —NH2 or —OH;
or a pharmaceutically acceptable salt thereof.

US Pat. No. 11,111,541

DIAGNOSTIC MIRNA MARKERS FOR PARKINSON'S DISEASE

Universitat Des Saarlande...


1. A method of analyzing miRNA in a blood sample taken from a patient, said method comprising the step of:a) determining in said blood sample expression level of: miRNA having the nucleotide sequence of SEQ ID NO: 142 and miRNA having the nucleotide sequence of SEQ ID NO: 59.

US Pat. No. 11,111,286

T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME AGAINST PRAME POSITIVE CANCERS


1. A method of treating a patient who has a PRAME positive cancer, wherein the PRAME positive cancer is capable of presenting a peptide consisting of the amino acid sequence of SLLQHLIGL (SEQ ID NO: 97) in the context of HLA-A*02 on the cell surface, comprising administering to the patient a population of transformed CD8+T cells expressing at least one vector encoding a T cell receptor (TCR),wherein the TCR comprisesan ? variable domain comprising CDR1?, CDR2?, and CDR3? of SEQ ID NO: 130, wherein the sequence of the ? variable domain is at least 95% identical to SEQ ID NO:130, and
a ? variable domain comprising CDR1?, CDR2?, and CDR3? of SEQ ID NO: 136, wherein the sequence of the ? variable domain is at least 95% identical to SEQ ID NO:136,

wherein the TCR is capable of binding to a peptide consisting of the amino acid sequence of SLLQHLIGL (SEQ ID NO: 97) in a complex with HLA-A*02, and
wherein the cancer is selected from acute lymphocytic cancer, acute myeloid leukemia, alveolar rhabdomyosarcoma, bone cancer, brain cancer, breast cancer, cancer of the anus, anal canal, or anorectum, cancer of the eye, cancer of the intrahepatic bile duct, cancer of the joints, cancer of the neck, gallbladder, or pleura, cancer of the nose, nasal cavity, or middle ear, cancer of the oral cavity, cancer of the vagina, cancer of the vulva, chronic lymphocytic leukemia, chronic myeloid cancer, colon cancer, esophageal cancer, cervical cancer, gastrointestinal carcinoid tumor, glioma, Hodgkin lymphoma, hypopharynx cancer, kidney cancer, larynx cancer, liver cancer, lung cancer, malignant mesothelioma, melanoma, multiple myeloma, nasopharynx cancer, non-Hodgkin lymphoma, cancer of the oropharynx, ovarian cancer, cancer of the penis, pancreatic cancer, peritoneum, omentum, and mesentery cancer, pharynx cancer, prostate cancer, rectal cancer, renal cancer, skin cancer, small intestine cancer, soft tissue cancer, stomach cancer, testicular cancer, thyroid cancer, cancer of the uterus, ureter cancer, and urinary bladder cancer.

US Pat. No. 11,111,542

METHOD FOR IDENTIFYING HIGH-RISK AML PATIENTS

UNIVERSITY HEALTH NETWORK...


1. A method of treating a human subject with acute myeloid leukemia (AML) comprising treating the subject with an aggressive cancer therapy, wherein the subject had been previously identified as being in a high risk group for worse survival by:(a) determining the gene expression level (GE level) of the following 17 genes in a test sample from the subject: DNMT3B, ZBTB46, NYNRIN, ARHGAP22, LAPTM4B, MMRN1, DPYSL3, KIAA0125, CDK6, CPXM1, SOCS2, SMIM24, EMP1, NGFRAP1, CD34, AKR1C3, GPR56;
(b) calculating a leukemia stem cell score (LSC Score) comprising the weighted sum expression of each of the 17 genes; and
(c) classifying the subject into the high risk group based on a high LSC Score in reference to a control cohort of AML patients.

US Pat. No. 11,110,258

LIQUID ANTIMICROBIAL DELIVERY SYSTEM (L.A.D.S.) TO HELP IMPROVE AUTOIMMUNE REGULATION


1. A Liquid Antimicrobial Delivery System designed to provide protection to a user exposed to bacteria, comprising;a measured amount of anti-microbial fluids;
an anti-bacteria glove having one or more liquid storage patches to store the anti-microbial fluids;
a collapsible tube container utilizing a ball and stem applicator to deliver a predetermined amount of the anti-microbial fluid;
the collapsible tube having a conical dome opening with first and second shut-off valves;
and
a face mask includes a liquid storage patch to store the anti-microbial fluids.

US Pat. No. 11,111,287

CHIMERIC PROTEINS AND METHODS OF IMMUNOTHERAPY

The Board of Trustees of ...


1. A system capable of inducing death of a target cell, comprising:(a) a chimeric transmembrane receptor polypeptide (receptor) comprising a ligand binding domain, an immune cell signaling domain, and a gene modulating polypeptide (GMP), the GMP comprising an actuator moiety linked to a cleavage recognition site, wherein the actuator moiety modulates expression and/or activity of an immune regulatory protein of the lymphocyte, and wherein the immune regulatory protein enhances lymphocyte cytotoxicity and/or reduces a side effect of lymphocyte activation; and
(b) a chimeric adaptor polypeptide (adaptor) comprising a receptor binding moiety linked to a cleavage moiety, wherein the cleavage moiety is capable of cleaving the cleavage recognition site on the receptor when the receptor binding moiety of the adaptor binds the immune cell signaling domain of the receptor in response to binding of the ligand binding domain of the receptor to a ligand present on the target cell, and wherein the adaptor does not bind a ligand present on the target cell,wherein the receptor is activatable upon binding to the ligand present on the target cell to recruit the adaptor to the receptor, and wherein the recruited adaptor releases the actuator moiety from the GMP of the receptor by action of the cleavage moiety at the cleavage recognition site to induce death of the target cell.


US Pat. No. 11,111,543

SYSTEM AND METHOD FOR CLEANING NOISY GENETIC DATA AND DETERMINING CHROMOSOME COPY NUMBER

Natera, Inc., San Carlos...


1. A method for determining genetic data for DNA from a subject, the method comprising:isolating DNA from a blood sample from the subject, wherein the DNA comprises DNA fragments;
amplifying a plurality of target loci from the DNA fragments to obtain amplification products, wherein adaptors comprising universal amplification sequences are ligated to the ends of the fragmented DNA or DNA derived therefrom, before amplifying the plurality of target loci and wherein the amplifying comprises nested PCR; and
using high throughput genotyping by sequencing by synthesis to detect genetic material from the amplification products and produce genetic data for the plurality of target loci on a chromosome or chromosome segment of interest.

US Pat. No. 11,111,288

CONDITIONALLY ACTIVE CHIMERIC ANTIGEN RECEPTORS FOR MODIFIED T-CELLS

BioAtla, Inc., San Diego...


1. A chimeric antigen receptor for binding with a tumor specific target antigen, comprising:i. at least one antigen specific targeting region evolved from a parent or wild-type protein or a domain thereof and having a decrease in activity in an assay at a normal physiological condition compared to the activity of the antigen specific targeting region in an assay at an aberrant condition that deviates from the normal physiological condition;
ii. a transmembrane domain; and
iii. an intracellular signaling domain;

wherein the tumor specific target antigen is selected from the group consisting of tyrosine kinase growth factor receptors that are overexpressed on a surface of a cancer cell.
US Pat. No. 11,111,544

SYSTEM AND METHOD FOR CLEANING NOISY GENETIC DATA AND DETERMINING CHROMOSOME COPY NUMBER

Natera, Inc., San Carlos...


1. A method for determining genetic data for DNA from a first individual in a biological sample of a second individual, the method comprising:amplifying a plurality of target loci on cell-free DNA extracted from the biological sample to generate amplified products;
sequencing the amplified products by sequencing-by-synthesis to obtain genetic data of the plurality of target loci;
determining the most likely genetic data for DNA from the first individual based on allele frequencies in the genetic data at the plurality of target loci.

US Pat. No. 11,111,289

ANTI-CGRP COMPOSITIONS AND USE THEREOF


1. A method of making Pichia pastoris or a CHO cell cultures which express an anti-CGRP antibody or antibody fragment, wherein said anti-CGRP antibody or antibody fragment comprises a variable light chain comprising CDRs comprising the amino acid sequences of SEQ ID NO: 55, 56 and 57 and a variable heavy chain comprising CDRs comprising the amino acid sequences of SEQ ID NO: 58, 59 and 60; comprising:(i) introducing at least one expression vector containing one or more heterologous polynucleotides encoding said antibody or antibody fragment operably linked to a promoter and a signal sequence into one or more Pichia pastoris or CHO cells;
(ii) culturing said Pichia pastoris or a CHO cells; and
(iii) selecting Pichia pastoris or CHO cell cultures that express said antibody.

US Pat. No. 11,111,545

METHODS FOR SIMULTANEOUS AMPLIFICATION OF TARGET LOCI

Natera, Inc., San Carlos...


1. A method for preparing a fraction of DNA useful for analyzing cancer-associated loci from an individual, comprising:(a) extracting DNA from a biological sample from the individual to obtain a sample of cell-free DNA (cfDNA);
(b) producing a fraction of the DNA extracted in (a) by amplifying at least 10 target loci relating to cancer-associated mutations to obtain amplification products that comprise the at least 10 target loci, wherein the amplifying comprises:(1) attaching adaptors to the cfDNA to produce adaptor-attached cfDNA, wherein the adaptors comprise universal priming sequences,
(2) a first PCR amplifying the at least 10 target loci comprising contacting the adaptor-attached cfDNA with a first universal primer and with at least 10 non-identical target specific primers in a single reaction volume, and
(3) a second, nested PCR amplifying the at least 10 target loci amplified in (2) comprising contacting the reaction products from (2) with a second universal primer and with at least 10 non-identical inner target specific primers in a single reaction volume, wherein the at least 10 target loci are single nucleotide variant (SNV) loci; and

(c) analyzing the at least 10 target loci in the fraction of DNA produced in (b).

US Pat. No. 11,111,290

ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF


1. A humanized monoclonal antibody comprising:(a) a Light Chain CDR1 having the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:31;
(b) a Light Chain CDR2 having the amino acid sequence of SEQ ID NO:4;
(c) a Light Chain CDR3 having the amino acid sequence of SEQ ID NO:5;
(d) a Heavy Chain CDR1 having the amino acid sequence of SEQ ID NO:6;
(e) a Heavy Chain CDR2 having the amino acid sequence of SEQ ID NO:7; and
(f) a Heavy Chain CDR3 having the amino acid sequence of SEQ ID NO:8 or SEQ ID NO:39.

US Pat. No. 11,111,546

3.4 KB MITOCHONDRIAL DNA DELETION FOR USE IN THE DETECTION OF CANCER

MDNA Life Sciences, Inc.,...


1. A method of detecting a cancer in an individual comprising;a) extracting mitochondrial DNA, mtDNA, from a biological sample from the individual;
b) quantifying the amount of a mtDNA deletion in the sample, the deletion having a nucleic acid sequence as set forth in SEQ ID NO: 1, the step of quantifying comprising the use of a pair of amplification primers, wherein one of the pair of amplification primers is adapted to bind to a rejoining site of the deletion after the deletion has re-circularized;
c) comparing the amount of the deletion in the sample to at least one known reference value.

US Pat. No. 11,111,291

CONJUGATES COMPRISING A VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) ANTIBODY AND A HYALURONIC ACID POLYMER

Genetech, Inc., South Sa...


1. An antibody conjugate comprising (i) an antibody that specifically binds to vascular endothelial growth factor (VEGF) and (ii) a hyaluronic acid (HA) polymer covalently attached to the antibody, wherein the HA polymer has a polydispersity index (PDI) of between 1.0 and 1.1.
US Pat. No. 11,111,547

TUMOR SUPPRESSOR REC8 AS A BIOMARKER FOR GASTRIC CANCER

The Chinese University of...


1. A method for reducing risk for gastric cancer in a subject, comprising the steps of:(a) treating DNA from a sample taken from the subject with an agent that differentially modifies methylated and unmethylated DNA, wherein the sample is a stomach mucosa sample or a plasma or serum sample;
(b) determining the number of methylated CpGs in a genomic sequence, which is SEQ ID NO:5 or a fragment thereof comprising at least 5 CpGs; and
(c) comparing the number of methylated CpGs from step (b) with the number of methylated CpGs in the genomic sequence from a non-cancer sample of the same type and processed through steps (a) and (b);
(d) determining the subject, whose sample contains more methylated CpGs in the genomic sequence determined in step (b) compared to the number of methylated CpGs in the genomic sequence from the non-cancer sample of the same type and processed through steps (a) to (b), as having an increased risk for gastric cancer compared with a healthy subject not diagnosed with gastric cancer; and
(e) subjecting the subject who is determined in step (d) as having an increased risk for gastric cancer to (i) reduction or elimination of consumption of foods preserved by drying, smoking, salting, or pickling; (ii) regular screening/examination by endoscopy; or (iii) testing for infection by Helicobacter pylori.

US Pat. No. 11,111,292

ANTI-IL-5 ANTIBODIES

CEPHALON, INC., Frazer, ...


1. A human antibody molecule that immunospecifically binds to human IL-5 with an equilibrium affinity constant (KD) of at least about 40 pM as determined by surface plasmon resonance, wherein the human antibody molecule comprises:a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 6, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 8, a light chain CDR1 comprising the amino acid sequence of SEQ ID NOs: 5, 21, 24, 27, 30, 33, 36, 39, or 66, a light chain CDR2 comprising the amino acid sequence of SEQ ID NOs: 7, 42, or 45, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NOs: 15, 48, 51, 54, 57, 60, or 63.

US Pat. No. 11,111,548

SYSTEMS AND METHODS FOR GENOTYPING SEED COMPONENTS

PIONEER HI-BRED INTERNATI...


1. A method of selecting maize embryonic tissue to culture into a plant with a known genotype comprising:(a) collecting shed cellular material from maize embryonic tissue in a container comprising the maize embryonic tissue and a non-destructive medium consisting essentially of an aqueous solution, wherein the shed cellular material was obtained by agitating the container without the addition of chemicals that would induce cell lysis;
(b) removing the maize embryonic tissue from the container comprising the shed cellular material and the non-destructive medium;
(c) obtaining DNA from the shed cellular material in the non-destructive medium consisting essentially of an aqueous solution;
(d) genotyping the DNA from the shed cellular material;
(e) selecting maize embryonic tissue to culture into a plant based on the genotype of the DNA from the shed cellular material; and
(f) culturing the maize embryonic tissue to produce a maize plant with a known genotype.

US Pat. No. 11,111,293

IL-18 BINDING MOLECULES

NOVARTIS AG, Basel (CH)


1. A method of inhibiting IL-18 biological activity in a mammalian patient in need thereof, which method comprises administering to the mammalian patient a therapeutically effective amount of an isolated antibody or fragment thereof that specifically binds IL-18 comprising:(i) a heavy chain variable region H-CDR1 comprising SEQ ID NO: 3 and
(ii) a heavy chain variable region H-CDR2 comprising SEQ ID NO: 4 or SEQ ID NO: 9 or SEQ ID NO: 10 or SEQ ID NO: 11 or SEQ ID NO: 12 or SEQ ID NO: 13 and
(iii) a heavy chain variable region H-CDR3 comprising SEQ ID NO: 5 and
(iv) a light chain variable region L-CDR1 comprising SEQ ID NO: 6 and
(v) a light chain variable region L-CDR2 comprising SEQ ID NO: 7 and
(vi) a light chain variable region L-CDR3 comprising SEQ ID NO: 8.

US Pat. No. 11,111,549

METHODS AND COMPOSITIONS FOR DETECTING CANDIDA SPECIES

GEN-PROBE INCORPORATED, ...


1. A method for determining the presence or absence of Candida species (sp.) in a sample, wherein the Candida sp. is one or more of C. albicans, C. parapsilosis, C. dubliniensis, C. tropicalis, and C. glabrata, the method comprising:(1) contacting a sample, said sample suspected of containing Candida sp., with a first amplification oligomer combination and a second amplification oligomer combination, wherein(a) the first amplification oligomer combination comprises first and second Candida-specific amplification oligomers for amplifying a first Candida sp. nucleic acid target region or a second Candida sp. nucleic acid target region, wherein said first target region corresponds to a region of SEQ ID NO:129 from about nucleotide position 133 or 161 to about nucleotide position 259 and said second region corresponds to a region of SEQ ID NO:130 from about nucleotide position 202 to about nucleotide position 308, and wherein the first and second Candida-specific amplification oligomers respectively comprise first and second Candida-specific target-hybridizing sequences, whereinthe first Candida-specific target-hybridizing sequence consists of the nucleotide sequence of residues 28-46 of SEQ ID NO:9; and
the second Candida-specific target-hybridizing sequence consists of the nucleotide sequence of SEQ ID NO:26; and

(b) the second amplification oligomer combination comprises first and second C. glabrata-specific amplification oligomers for amplifying a third Candida sp. nucleic acid target region, wherein said third target region corresponds to a region of SEQ ID NO:131 from about nucleotide position 355 to about nucleotide position 554, and wherein the first and second C. glabrata-specific amplification oligomers respectively comprise first and second C. glabrata-specific target-hybridizing sequences, whereinthe first C. glabrata-specific target-hybridizing sequence is a sequence of from 15 to 24 contiguous nucleotides contained in the sequence of SEQ ID NO:134 and that includes at least the sequence of SEQ ID NO:135; and/or
the second C. glabrata-specific target-hybridizing sequence is a sequence of from 16 to 21 contiguous nucleotides contained in the sequence of SEQ ID NO:136 and that includes at least the sequence of SEQ ID NO:137;

wherein each of the first Candida-specific amplification oligomer and the first C. glabrata-specific amplification oligomer is a promoter primer or promoter provider further comprising a promoter sequence located 5? to the respective target-hybridizing sequence, and
wherein each of the second Candida-specific amplification oligomer and the second C. glabrata-specific amplification oligomer is a non-promoter primer;

(2) performing a transcription-mediated amplification (TMA) reaction, wherein any Candida sp. target nucleic acid, if present in the sample, is used as a template for generating one or more amplification products corresponding to at least one of the first, second, and third target regions; and
(3) detecting in real time the presence or absence of the one or more amplification products, thereby determining the presence or absence of Candida sp. in the sample, wherein said detection comprises (i) contacting one or more amplification products with a Candida-specific detection probe that specifically hybridizes to the first or second Candida sp. target region and a C. glabrata-specific detection probe that specifically hybridizes to the third Candida sp. target region, wherein each of the Candida-specific and C. glabrata-specific detection probes is a molecular torch, and (ii) detecting the presence or absence of any hybridized Candida-specific or C. glabrata-specific detection probe.

US Pat. No. 11,111,294

T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME


1. A method of treating a patient who has acute myeloid leukemia, comprising administering to the patient a population of transformed T cells expressing at least one vector encoding a T cell receptor (TCR),wherein the TCR comprises an alpha chain and a beta chain,wherein the alpha chain comprises SEQ ID NOs: 97, 98, and 99, and the beta chain comprises SEQ ID NOs: 103, 104, and 105,

wherein the TCR binds to a peptide consisting of the amino acid sequence of ALSVLRLAL (SEQ ID NO: 133) in a complex with an MHC class I molecule.

US Pat. No. 11,111,295

ANTIBODY FOR ANTI-CLAUDIN 18A2 AND USE THEREOF

CAFA THERAPEUTICS LIMITED...


1. An antibody or antigen binding unit thereof that specifically binds to claudin 18A2, wherein,(a) HCDR1 is SEQ ID NO:31, HCDR2 is SEQ ID NO:32, HCDR3 is SEQ ID NO:33, LCDR1 is SEQ ID NO:34, LCDR2 is SEQ ID NO:35, and LCDR3 is SEQ ID NO:36;
(b) HCDR1 is SEQ ID NO:37, HCDR2 is SEQ ID NO:38, HCDR3 is SEQ ID NO:39, LCDR1 is SEQ ID NO: 40, LCDR2 is SEQ ID NO: 41, and LCDR3 is SEQ ID NO:42;
(c) HCDR1 is SEQ ID NO:43, HCDR2 is SEQ ID NO:44, HCDR3 is SEQ ID NO:45, LCDR1 is SEQ ID NO:46, LCDR2 is SEQ ID NO:47, and LCDR3 is SEQ ID NO:48;
(d) HCDR1 is SEQ ID NO:49, HCDR2 is SEQ ID NO:50, HCDR3 is SEQ ID NO:51, LCDR1 is SEQ ID NO:52, LCDR2 is SEQ ID NO:53, and LCDR3 is SEQ ID NO:54;
(e) HCDR1 is SEQ ID NO:31, HCDR2 is SEQ ID NO:83, HCDR3 is SEQ ID NO:33, LCDR1 is SEQ ID NO:34, LCDR2 is SEQ ID NO:35, and LCDR3 is SEQ ID NO:36;
(f) HCDR1 is SEQ ID NO:31, HCDR2 is SEQ ID NO:84, HCDR3 is SEQ ID NO:33, LCDR1 is SEQ ID NO:34, LCDR2 is SEQ ID NO:35, and LCDR3 is SEQ ID NO: 36; or
(g) HCDR1 is SEQ ID NO:49, HCDR2 is SEQ ID NO:85, HCDR3 is SEQ ID NO:51, LCDR1 is SEQ ID NO:52, LCDR2 is SEQ ID NO:53, and LCDR3 is SEQ ID NO: 54.

US Pat. No. 11,111,296

COMPOSITIONS AND METHODS FOR TREATING CARDIAC DYSFUNCTION

THE BROAD INSTITUTE, INC....


1. A method for synthesizing a candidate compound that binds to a site on a RAGE polypeptide, the method comprising:(a) accessing, by a computer, a three-dimensional structure of a RAGE polypeptide having at least one atomic coordinate, or surrogate thereof, from Protein Data Bank (PDB) ID: 4LP4 for each of the amino acid residues 23-54 or for each of the amino acid residues 25, 54, 59, 61, 91, 92, 94, 96, 98, 114, 116, 150, 151, 152, 154, 175, 177, 178, 179, 186, 213 and 216 of the RAGE polypeptide, or having atomic coordinates that have a root mean square deviation of the coordinates of less than 3 angstroms;
(b) screening, by the computer, each chemical compound fragment in a set of chemical compound fragments having a three dimensional structure that interacts with the three-dimensional structure of the RAGE polypeptide accessed in step (a) by determining a subset of the chemical compound fragments in the set of the chemical compound fragments that have one or more different orientations of the three-dimensional structure of the subset of the chemical compound fragments that are complementary to a binding site of the three-dimensional structure of the RAGE polypeptide to structurally model a specific interaction of the with the binding site on the RAGE polypeptide;
(c) selecting, by the computer, a candidate compound structure comprising a selection of chemical compound fragments in the subset of the chemical compound fragments, wherein the selection of chemical compound fragments (i) specifically interact with a binding site of the RAGE polypeptide based on step (b), and/or (ii) possesses one or both of steric fit and electrostatic complementarity to the binding site of the RAGE polypeptide, and wherein the candidate compound structure defines a molecule having sufficient surface complementary to the RAGE polypeptide to specifically bind to the site on the RAGE polypeptide in an aqueous solution;
(d) assembling, by the computer, the subset of the chemical compound fragments of the candidate compound structure into a single compound structure; and
(e) synthesizing the single compound structure that binds to a site on a RAGE polypeptide so as to regulate RAGE-mediated cachetogenic activity.

US Pat. No. 11,114,654

NEGATIVE ELECTRODE ACTIVE MATERIAL HAVING HIGH OUTPUT CHARACTERISTICS AND LITHIUM SECONDARY BATTERY INCLUDING THE SAME

LG CHEM, LTD., Seoul (KR...


1. A negative electrode active material comprising:lithium titanium oxide particles,wherein the lithium titanium oxide particles have an average particle diameter (D50) of 0.5-9 ?m, a specific surface area of 3-7 m2/g, and a pellet density of 1.7 g/cc or more under a pressure of 64 MPa, and the lithium titanium oxide is represented by the following Chemical Formula 1,

wherein the lithium titanium oxide particles are a mixture of primary particles with secondary particles, and a weight ratio of the primary particles to the secondary particles is between 1:9 and 4:6:
[Chemical Formula 1]LixTiyOzMw

Wherein M is any one selected from the group consisting of Zr, B, Sn, S, Be, Ge and Zn, or a combination of two or more of them, 0.5?x?5, 1?y?5, 2?z?12, and 0?w<0.1.

US Pat. No. 11,111,297

ANTIBODIES SPECIFIC FOR IMMUNOGLOBULIN-LIKE TRANSCRIPT 3 (ILT3) AND USES THEREOF


1. An antibody or antigen binding fragment that binds the extracellular domain of human immunoglobulin-like transcript 3 (ILT3) having amino acids 1-238 of SEQ ID NO: 1, wherein the antibody or antigen binding fragment comprises(a) a heavy chain complementarity determining region 1 (HC-CDR1), wherein the HC-CDR1 has the amino acid sequence set forth in SEQ ID NO: 17; an HC-CDR2, wherein the HC-CDR2 has the amino acid sequence set forth in SEQ ID NO: 19, 20, or 21; an HC-CDR3, wherein the HC-CDR3 has the amino acid sequence set forth in SEQ ID NO: 23; and
(b) a light chain complementarity determining region 1 (LC-CDR1), wherein the LC-CDR1 has the amino acid sequence set forth in SEQ ID NO: 34, 35, 36, 37, 38, 39, 40, 41, or 42; an LC-CDR2, wherein the LC-CDR2 has the amino acid sequence set forth in SEQ ID NO: 43; and an LC-CDR3, wherein the LC-CDR3 has the amino acid sequence set forth in SEQ ID NO: 44.

US Pat. No. 11,114,655

ALKALINE BATTERY CATHODE WITH SOLID POLYMER ELECTROLYTE

IONIC MATERIALS, INC., W...


1. A battery comprising:an electrode that includes:
an electrically conductive material; and
a solid ionically conducting polymer material;
wherein the solid ionically conducting polymer material has an ionic conductivity greater than 1×10?6 S/cm at room temperature;
wherein the solid ionically conducting polymer material is the reaction product of a synthesis reaction of a mixture of a base polymer and an ionic compound heated in the presence of a gas;
wherein the gas is a dopant selected from the group consisting of oxygen, air and ozone, and functions as an electron acceptor or oxidant;
wherein the base polymer is polyphenylene sulfide; and
wherein the ionic compound is selected from the group consisting of an inorganic oxide, an inorganic chloride and an inorganic hydroxide.

US Pat. No. 11,111,298

T CELL-ANTIGEN COUPLER WITH VARIOUS CONSTRUCT OPTIMIZATIONS

McMaster University, Ham...


1. A BCMA (B Cell Maturation Antigen) T cell-antigen coupler (BCMA-TAC) polypeptide, comprising the amino acid sequence set forth in SEQ ID NO: 56, SEQ ID NO: 58, SEQ ID NO: 60, or SEQ ID NO: 62.
US Pat. No. 11,111,299

CD3-BINDING MOLECULES CAPABLE OF BINDING TO HUMAN AND NON-HUMAN CD3

MacroGenics, Inc., Rockv...


1. A CD3-binding molecule comprising an antigen-binding fragment of an antibody, wherein said antigen-binding fragment comprises an antibody CD3-specific VL domain and an antibody CD3-specific VH domain, wherein said CD3-specific VL domain and said CD3-specific VH domain form an antigen-binding domain capable of immunospecifically binding to both an epitope of human CD3 and to an epitope of the CD3 of a non-human mammal, wherein:(I) said CD3-specific VL domain comprises the three complementarity determining regions (CDRs) of SEQ ID NO:5; and
(II) said CD3-specific VH domain comprises the three complementarity determining regions (CDRs) of SEQ ID NO:7, modified to comprise one or more amino acid substitutions selected from the group consisting of:(i) I51T;
(ii) S52aN;
(iii) Y52cA;
(iv) N54S;
(v) A56T;
(vi) Y58E;
(vii) D61A; and
(viii) D65G;

wherein said numbering is according to the Kabat numbering scheme.

US Pat. No. 11,111,300

ANTI PD-L1 ANTIBODIES

APOLLOMICS INC., Foster ...


1. A method for treating a PD-L1 expressing cancer in a human subject having the PD-L1 expressing cancer, the method comprising administering to the subject an antibody or fragment thereof that binds to PD-L1, wherein the antibody or fragment thereof comprises:(i) a heavy chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO: 93, 94, and 95, respectively, and a light chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO: 96, 97, and 98, respectively;
(ii) a heavy chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO: 81, 82, and 83, respectively, and a light chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO: 84, 85, and 86, respectively;
(iii) a heavy chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO: 87, 88, and 89, respectively, and a light chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO: 90, 91, and 92, respectively;
(iv) a heavy chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO: 99, 100, and 101, respectively, and a light chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO: 102, 103, and 104, respectively;
(v) a heavy chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO: 105, 106, and 107, respectively, and a light chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO: 108, 109, and 110, respectively;
(vi) a heavy chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO: 111, 112, and 113, respectively, and a light chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO: 114, 115, and 116, respectively;
(vii) a heavy chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO: 117, 118, and 119, respectively, and a light chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO: 120, 121, and 122, respectively;
(viii) a heavy chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO: 123, 124, and 125, respectively, and a light chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO: 126, 127, and 128, respectively;
(ix) a heavy chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO: 129, 130, and 131, respectively, and a light chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO: 132, 133, and 134, respectively; or
(x) a heavy chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO: 135, 136, and 137, respectively, and a light chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO: 138, 139, and 140, respectively.

US Pat. No. 11,111,557

NON-ORIENTED ELECTRICAL STEEL SHEET AND MANUFACTURING METHOD THEREFOR

POSCO, Pohang-Si (KR)


1. A non-oriented electrical steel sheet, comprising:Si: 2.0 to 3.5%, Al: 0.05 to 2.0%, Mn: 0.05 to 2.0%, In: 0.0002 to 0.003%, Bi: 0.0005 to 0.05 by wt % and Fe and inevitable impurities as the remainder.

US Pat. No. 11,111,301

T CELL MODIFICATION AND USE THEREOF

Adaptimmune Ltd, Oxfords...


1. A method of treating cancer using immunotherapy, comprising administering to a patient having cancer a population of modified T cells comprising a nucleic acid construct, wherein the cancer expresses one or more tumor antigens selected from NY-ESO1, PRAME, alpha-fetoprotein (AFP), MAGE A4, MAGE A1, MAGE A10 and MAGE B2; and wherein the nucleic acid construct comprises:(i) a first nucleotide sequence encoding IL 7,
(ii) a second nucleotide sequence encoding an antigen receptor, wherein the antigen receptor is a chimeric antigen receptor (CAR) that binds to said one or more tumor antigens, or a T cell receptor (TCR) that binds to an MHC-displayed peptide fragment of said one or more tumor antigens;
(iii) an inducible promoter operably linked to the first nucleotide sequence; and
(iv) a constitutive promoter operably linked to the second nucleotide sequence wherein the administration of said modified T cells results in the treatment of the patient's cancer.

US Pat. No. 11,111,558

HOT-PRESSED MEMBER AND METHOD FOR MANUFACTURING SAME, AND COLD-ROLLED STEEL SHEET FOR HOT PRESSING AND METHOD FOR MANUFACTURING SAME

JFE STEEL CORPORATION, T...


1. A hot-pressed member comprising:a steel chemical composition containing, by mass %, C: 0.28% or more and less than 0.42%, Si: 1.5% or less, Mn: 1.0% or more and 2.4% or less, P: 0.05% or less, S: 0.005% or less, Al: 0.01% or more and 0.50% or less, N: 0.005% or less, Nb: 0.005% or more and 0.15% or less, Ti: 0.005% or more and 0.15% or less, and B: 0.0005% or more and 0.0050% or less, where among the components of the member, C, Si, Nb, Ti, N, and B satisfy the following Expression (1),(Nb+(Ti?3.4N)+100B)/((C/8)+Si)?0.25??(1)


where each element symbol represents the content by mass % of the corresponding element, with the balance being Fe and inevitable impurities;a microstructure in whicha prior austenite average grain size is 7.5 ?m or less, a volume fraction of martensite is 95% or more, and at least 10 Nb-based and Ti-based precipitates having a grain size of less than 0.10 ?m are present on average per 100 ?m2 of a cross section parallel to a thickness direction of the member within a range of 100 ?m in the thickness direction from a surface of the member;

a B concentration in prior austenite grain boundaries being at least 3.0 times a B concentration at a position 5 nm away from the grain boundaries; and
a tensile strength of 1780 MPa or more.

US Pat. No. 11,114,659

NEGATIVE ELECTRODE SHEET AND SECONDARY BATTERY

Contemporary Amperex Tech...


1. A secondary battery, comprising a negative electrode sheet, wherein the negative electrode sheet comprises:a negative current collector and a negative electrode film provided on at least one surface of the negative current collector and comprising a negative active substance;
wherein
the negative electrode sheet further satisfies 0.3?a×(1.1/b+0.02×c)?6.0;
wherein
a represents a specific surface area of the negative electrode film, and a unit is m2/g;
b represents compaction density of the negative electrode film, and a unit is g/cm3; and
c represents cohesive force between the negative electrode film and the negative current collector, and a unit is N/m.

US Pat. No. 11,111,302

ANTI HLA-G SPECIFIC ANTIBODIES

Invectys SA, Paris (FR)


1. An anti-human leukocyte antigen G (HLA-G) antibody or an antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment comprises:(a) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (HC CDR1) of SEQ ID NO: 8, a heavy chain complementarity determining region 2 (HC CDR2) of SEQ ID NO: 10, and a heavy chain complementarity determining region 3 (HC CDR3) of SEQ ID NO: 12; and
(b) a light chain variable region (VL), which comprises a light chain complementarity determining region 1 (LC CDR1) of SEQ ID NO: 2, a light chain complementarity determining region 2 (LC CDR2) of sequence KVS and a light chain complementarity determining region 3 (LC CDR3) of SEQ ID NO: 5.

US Pat. No. 11,111,559

PROCESS FOR RECOVERING PRECIOUS METALS FROM CLAY-CONTAINING ORES

Ethox Chemicals, LLC, Gr...


20. A method for heap leaching of precious metal from day containing ore comprising:forming a heap of ore on a leach bed;
percolating a leach solution through said heap wherein said leach solution comprises:cyanide;
a wetting agent; and
a clay stabilizing polymer;

thereby forming a pregnant leach solution comprising said precious metal; and
removing said precious metal from said pregnant leach solution; and

wherein said wetting agent is selected from the group consisting of alcohol ethoxylates; polyethylene glycol esters, hydrophilic modified silicones, and fatty amine ethoxylates.
US Pat. No. 11,111,303

COMPOSITIONS AND METHODS FOR ACTIVATION OF NK CELLS KILLING OF PROSTATE CANCER AND BREAST CANCER CELLS

UNIVERSITY OF NORTH TEXAS...


1. A method for treating breast cancer or prostate cancer in a patient in need of such treatment, comprising administering to the patient an antibody or antibody fragment that binds LLT1, the antibody or antibody fragment comprising heavy chain complementarity-determining regions (CDRs) having an amino acid sequence of SEQ ID NO:11, SEQ ID NO:12, and SEQ ID NO:13, and light chain CDRs having an amino acid sequences of SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17, wherein the antibody or antibody fragment binds to cancer cells and inhibits cancer growth or progression.
US Pat. No. 11,111,560

GREY GOLD ALLOY

SIMON G. JEWELRY, INC., ...


1. An alloy consisting of:from 50% to 60% by weight gold, from 20% to 40% by weight palladium, from 0.1% to 11% by weight silver, from greater than 0 to 17% by weight copper, from greater than 0 to 13% by weight zinc, and from greater than 0 to 10% by weight bismuth.

US Pat. No. 11,111,304

FULLY HUMAN ANTIBODIES THAT BIND TO VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (VEGFR2)

Sorrento Therapeutics, In...


1. A recombinant fully human anti-vascular endothelial growth factor receptor 2 (VEGFR2) antibody, or an antigen binding fragment thereof, that binds to VEGFR2 comprising complementarity determining regions (CDRs) as set forth in a heavy chain variable domain amino acid sequence selected from the group consisting of SEQ ID NO. 9, SEQ ID NO. 23, SEQ ID NO. 51, SEQ ID NO. 63, SEQ ID NO. 73 and SEQ ID NO. 77, and comprising CDRs as set forth in a light chain variable domain amino acid sequence selected from the group consisting of SEQ ID NO. 10, SEQ ID NO. 24, SEQ ID NO. 52, SEQ ID NO. 64, SEQ ID NO. 78, and SEQ ID NO. 81.
US Pat. No. 11,111,305

METHOD OF USING A BISPECIFIC ANTIBODY TO CONDITIONALLY INHIBIT A RECEPTOR SIGNALING COMPLEX

TORCH THERAPEUTICS, Hill...


1. A method of conditionally inhibiting a receptor signaling complex (RSC) comprising a receptor protein and a receptor ligand in a target cell comprising:a) providing a cell capable of forming said receptor signaling complex, wherein said receptor protein binds said ligand at an active site;
b) contacting said cell with a bispecific antibody comprising:i) a first antigen binding domain that binds to said receptor protein at a first epitope outside of said active site;
ii) a second antigen binding domain that binds to a target protein;

c) wherein if said cell expresses said target protein, said first antigen binding domain binds to said receptor protein and said second antigen binding domain binds to said target protein, thereby inhibiting the binding of said receptor protein and said ligand to reduce signaling; and
d) wherein if said cell does not express said target protein, said first antigen binding domain binds to said receptor protein and does not prevent binding of said ligand to said receptor protein to achieve receptor signaling, and
e) and wherein said receptor protein/target protein pair is selected from the group consisting of Type II Receptor for TGF? (TGFBR2)/CD45, TGFBR2/Fibroblast Activation Protein (FAP), TGFBR2/Beta-3 Adrenergic Receptor (ADRB3), Colony Stimulating Factor 2 Receptor Alpha Subunit (GMCSFR?)/CD33, Signal-Regulatory Protein Alpha (SIRP?)/Programmed death-ligand 1 (PD-L1), Interleukin 2 Receptor (IL2R)/Layilin (LAYN), Program cell death protein 1 (PD-1)/Potassium Calcium-Activated Channel Subfamily M Alpha 1 (KCNMA1) and Glycoprotein 130 (gp130)/PD-L1.

US Pat. No. 11,111,306

IL-7R-ALPHA SPECIFIC ANTIBODIES FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA

The United States of Amer...


1. A method of treating a subject with an IL-7R? positive cancer or with an autoimmune disease, comprising:administering to the subject a therapeutically effective amount of:(A) a monoclonal antibody that specifically binds to an extracellular domain of IL-7R?, the monoclonal antibody comprising:
a heavy chain variable region (VH) comprising a heavy chain complementarity determining region (HCDR)1, a HCDR2, and a HCDR3 of the VH set forth as SEQ ID NO: 1 (4A10 VH) and a light chain variable region (VL) comprising a light chain complementarity determining region (LCDR)1, a LCDR2, and a LCDR3 of the VL set forth as SEQ ID NO: 2 (4A10 VL), or
a VH comprising a HCDR1, a HCDR2, and a HCDR3 of the VH set forth as SEQ ID NO: 3 (2B8 VH) and a VL comprising a LCDR1, a LCDR2, and a LCDR3 of the VL set forth as SEQ ID NO: 4 (2B8 VL);
(B) an antigen binding fragment of the monoclonal antibody; or
(C) a bispecific antibody comprising the monoclonal antibody or the antigen binding fragment; and

administering to the subject a therapeutically effective amount of an additional agent, thereby treating the IL-7R? positive cancer or the autoimmune disease in the subject.

US Pat. No. 11,111,307

ANTI-BCMA ANTIBODIES

Biogen MA Inc., Cambridg...


1. An isolated polypeptide comprising an antigen binding fragment of an antibody that binds to the polypeptide of SEQ ID NO:9, wherein the antigen binding fragment of the antibody comprises:a) a heavy chain variable domain comprising CDR1, CDR2, and CDR3 of the amino acid sequence of SEQ ID NO: 1 and a light chain variable domain comprising CDR1, CDR2, and CDR3 of the amino acid sequence of SEQ ID NO: 2;
b) a heavy chain variable domain comprising CDR1, CDR2, and CDR3 of the amino acid sequence of SEQ ID NO: 3 and a light chain variable domain comprising CDR1, CDR2, and CDR3 of the amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 11, or SEQ ID NO: 12;
c) a heavy chain variable domain comprising CDR1, CDR2, and CDR3 of the amino acid sequence of SEQ ID NO: 5 and a light chain variable domain comprising CDR1, CDR2, and CDR3 of the amino acid sequence of SEQ ID NO: 6; or
d) a heavy chain variable domain comprising CDR1, CDR2, and CDR3 of the amino acid sequence of SEQ ID NO: 7 and a light chain variable domain comprising CDR1, CDR2, and CDR3 of the amino acid sequence of SEQ ID NO: 8.

US Pat. No. 11,111,308

ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODY CAPABLE OF PENETRATING BLOOD-BRAIN BARRIER

JCR Pharmaceuticals Co., ...


1. An anti-human transferrin receptor antibody, wherein the heavy chain variable region of the antibody comprises,(a) CDR1 comprising the amino acid sequence of SEQ ID NO: 62 or SEQ ID NO: 63,
(b) CDR2 comprising the amino acid sequence of SEQ ID NO: 13 or SEQ ID NO: 14, and
(c) CDR3 comprising the amino acid sequence of SEQ ID NO: 15 or SEQ ID NO: 16, and the light chain variable region of the antibody comprises,
(a) CDR1 comprising the amino acid sequence of SEQ ID NO: 6,
(b) CDR2 comprising the amino acid sequence of SEQ ID NO: 8, and
(c) CDR3 comprising the amino acid sequence of SEQ ID NO: 10.

US Pat. No. 11,114,666

MODIFIED GRAPHITE NEGATIVE ELECTRODE MATERIAL, PREPARATION METHOD THEREOF AND SECONDARY BATTERY

Ningde Amperex Technology...


1. A method for preparing a modified graphite negative electrode material, comprising steps of:adding a multilayer graphene, a conductive agent and a binder to a reactor of a mechanical fusion machine under a protective gas atmosphere, setting a rotation speed and raising the temperature so that the multilayer graphene are loaded with the conductive agent by the bonding of the binder;
adding the multilayer graphene loaded with the conductive agent and the graphite to a mixer for mixing, screening and demagnetizing after mixing, to obtain the modified graphite negative electrode material,
wherein the modified graphite negative electrode material comprises: a graphite; and
a multilayer graphene dispersed in the graphite;
wherein,
the multilayer graphene are loaded with a conductive agent by bonding of a binder, and
wherein the multilayer graphene has a true density of 1.8 g/cm3 to 2.15 g/cm3.

US Pat. No. 11,111,309

METHOD OF REDUCING EXPRESSION OF DUX4 IN A MUSCLE CELL BY ADMINISTERING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE TARGETING DUX4

Dyne Therapeutics, Inc., ...


1. A method of reducing expression level of DUX4 in a muscle cell of a subject, the method comprising administering to the subject a complex that comprises an anti-transferrin receptor antibody covalently linked to an oligonucleotide that targets a DUX4 RNA,wherein the anti-transferrin receptor antibody binds in the range of C89 to F760 of human transferrin receptor protein 1 (TfR1) having an amino acid sequence as set forth in SEQ ID NO: 1 and wherein the anti-transferrin receptor antibody does not specifically bind to the transferrin binding site of TfR1;
wherein the oligonucleotide is a single stranded oligonucleotide in the range of 15-35 nucleotides in length, wherein the oligonucleotide comprises a region of complementarity to the nucleotide sequence as set forth in SEQ ID NO: 46, wherein the region of complementarity is at least 15 nucleotides in length, and wherein the oligonucleotide is a phosphorodiamidate morpholino oligomer; and
wherein the complex is administered to the subject by infusion and the oligonucleotide brings about reduction of expression level of DUX4 in the muscle cell.

US Pat. No. 11,114,667

ELECTRODE-FORMING COMPOSITION

Solvay SA, Brussels (BE)...


1. An electrochemical device being a secondary battery comprising:a positive electrode,
a negative electrode, and
between said positive electrode and said negative electrode, a membrane, wherein:
A) at least one of said positive electrode and said negative electrode is an electrode obtainable by a process, said process comprising:(i) providing a metal substrate;
(ii) providing an electrode-forming composition (C1) comprising:at least one polymer (FF), wherein polymer (FF) is a partially fluorinated fluoropolymer comprising linear sequences of recurring units derived from at least one fluorinated monomer and at least one functional hydrogenated monomer comprising at least one carboxylic acid end group,
at least one electro-active compound (EA),
at least one liquid medium (L) comprising at least one organic carbonate or at least one ionic liquid, and
at least one metal salt (M);

(iii) applying the composition provided in step (ii) onto the metal substrate provided in step (i) thereby providing an assembly comprising a metal substrate coated with at least one layer consisting of said composition (C1); and
(iv) drying the assembly provided in step (iii);
wherein said electrode comprises:the metal substrate, and
directly adhered onto said metal substrate, at least one laver (L1) consisting of a composition (C2) comprising:
at least one partially fluorinated fluoropolymer (FF) comprising linear sequences of recurring units derived from at least one fluorinated monomer and at least one functional hydrogenated monomer comprising at least one carboxylic acid end group,
at least one electroactive compound (EA),
at least one liquid medium (L) comprising at least one organic carbonate or at least one ionic liquid, and
at least one metal salt (M),


B) the membrane comprises a fluoropolymer hybrid organic/inorganic composite, said fluoropolymer hybrid organic/inorganic composite being obtained by a process comprising hydrolysing and/or condensing a composition comprising:at least one partially fluorinated fluoropolymer,
at least one metal compound (M1) of formula (IV):X4-mAYm??(IV)

wherein m is an integer from 1 to 4, A is a metal selected from the group consisting of Si, Ti and Zr, Y is a hydrolysable group and X is a hydrocarbon group, optionally comprising one or more functional groups,
at least one ionic liquid, and
at least one metal salt (M).


US Pat. No. 11,111,310

CHIMERIC POLYPEPTIDES AND METHODS OF ALTERING THE MEMBRANE LOCALIZATION OF THE SAME

Cell Design Labs, Inc., ...


1. A single-chain chimeric polypeptide, wherein the single-chain chimeric polypeptide comprises:a transmembrane domain; and
a hormone receptor ligand binding domain,
wherein:
the transmembrane domain and the hormone receptor ligand binding domain directly abut each other or are separated by 1 to 500 amino acids;
the transmembrane domain and the hormone receptor ligand binding domain are not both present in the same endogenous single-chain polypeptide in a mammal; and
wherein the hormone receptor ligand binding domain is a ligand binding domain of a steroid receptor.

US Pat. No. 11,111,311

ANTI-DLL3 ANTIBODY

CHUGAI SEIYAKU KABUSHIKI ...


1. An antibody that binds to DLL3 having the amino acid sequence of SEQ ID NO: 1, wherein said antibody binds to a region between amino acids 216 to 492 of SEQ ID NO: 1, wherein the antibody has an internalizing activity and is either conjugated to, or is capable of being conjugated to, one or more cytotoxic substances,and wherein the anti-DLL3 antibody is
an antibody comprising a heavy chain variable region comprising heavy chain CDR1 having the amino acid sequence as set forth in SEQ ID NO: 36, heavy chain CDR2 having the amino acid sequence as set forth in SEQ ID NO: 37, and heavy chain CDR3 having the amino acid sequence as set forth in SEQ ID NO: 38, and a light chain variable region comprising light chain CDR1 having the amino acid sequence as set forth in SEQ ID NO: 42, light chain CDR2 having the amino acid sequence as set forth in SEQ ID NO: 43, and light chain CDR3 having the amino acid sequence as set forth in SEQ ID NO: 44.

US Pat. No. 11,111,568

STEEL FOR COLD FORGING AND MANUFACTURING METHOD THEREOF

NIPPON STEEL CORPORATION,...


1. A steel for cold forging comprising, as a chemical composition, by mass %,C: 0.05% to 0.30%,
Si: 0.05% to 0.45%,
Mn: 0.40% to 2.00%,
S: 0.008% to less than 0.040%,
Cr: 0.01% to 3.00%,
Al: 0.010% to 0.100%,
Bi: 0.0001% to 0.0050%,
Mo: 0% to 1.00%,
Ni: 0% to 1.00%,
V: 0% to 0.30%,
B: 0% to 0.0200%,
Mg: 0% to 0.0035%,
Ti: 0% to 0.060%,
Nb: 0% to 0.080%, and
a remainder of Fe and impurities,
wherein N, P, and O contained in the impurities are as followsN: 0.0250% or less,
P: 0.050% or less, and
O: 0.0020% or less,

1200/mm2 or more of sulfides having an equivalent circle diameter of 1.0 to 10.0 ?m are contained in a microstructure,
an average distance between the sulfides is less than 30.0 ?m, and
the sulfides in the microstructure satisfy Expression (1) and Expression (2):
d+3??10.0 . . . (1)
SA/SB<0.30 . . . (2),
in Expression (1), d is an average value of equivalent circle diameters of the sulfides having an equivalent circle diameter of 1.0 ?m or more, ? is a standard deviation of the equivalent circle diameters of the sulfides having the equivalent circle diameter of 1.0 ?m or more, in Expression (2), SA is a number of sulfides having the equivalent circle diameter of 1.0 ?m or more and less than 3.0 ?m, and SB is a number of sulfides having an equivalent circle diameter of 1.0 ?m or more.

US Pat. No. 11,114,670

NEGATIVE ELECTRODE AND METHOD FOR PREPARING NEGATIVE ELECTRODE

LG CHEM, LTD., Seoul (KR...


1. A negative electrode comprising:a current collector; and
a negative electrode active material layer disposed on the current collector,
wherein the negative electrode active material layer includes first particles, second particles and third particles,
each first particle comprises a first core including artificial graphite; and a first shell disposed on the first core, said first shell including an oxide of the artificial graphite, a sphericity of each first particle measured through a particle shape analyzer is from 0.94 to 0.98,
each second particle is artificial graphite having a sphericity measured through the particle shape analyzer of 0.70 to 0.92,
each third particle comprises a second core including natural graphite; and a second shell disposed on the second core, said second shell including an oxide of the natural graphite, and each third particle having a sphericity measured through the particle shape analyzer from 0.94 to 0.98, and
a weight ratio of first particles to second particles is from 1:1 to 1:9.

US Pat. No. 11,111,312

MUTANT INTERLEUKIN-2 POLYPEPTIDES

ROCHE GLYCART AG, Schlie...


1. An isolated polynucleotide encoding a polypeptide of an immunoconjugate, wherein the immunoconjugate comprises a mutant interleukin-2 (IL-2) polypeptide and an immunoglobulin molecule that specifically binds Fibroblast Activation Protein (FAP), and the isolated polynucleotide comprising the sequence of SEQ ID NO: 302.
US Pat. No. 11,111,569

NON-HEAT TREATED STEEL BAR

Nippon Steel Corporation,...


1. A non-heat treated steel bar comprising a chemical composition consisting of, in mass percent:C: 0.39 to 0.55%;
Si: 0.10 to 1.00%;
Mn: 0.50 to 1.50%;
P: 0.010 to 0.100%;
S: 0.040 to 0.130%;
Cr: 0.05 to 0.50%;
V: 0.05 to 0.40%;
Ti: 0.10% to 0.25%;
Al: 0.003 to 0.100%;
N: 0.020% or less;
Cu: 0 to 0.40%;
Ni: 0 to less than 0.20%;
Mo: 0 to 0.10%;
Pb: 0 to 0.30%;
Te: 0 to 0.3000%;
Ca: 0 to 0.0100%; and
Bi: 0 to 0.3000%, with the balance being Fe and impurities including oxygen, the chemical composition satisfying Formula (1), wherein
in the steel bar, a number density of Al2O3-based inclusions in each of which Al2O3is contained at 70.0% or more in mass percent and ?AREA is not less than 3 ?m is 0.05 to 1.00/mm2:0.60?C+0.2Mn+0.25Cr+0.75V+0.81Mo?1.00??(1)

where symbols of elements in Formula (1) are to be substituted by contents of corresponding elements (in mass percent).

US Pat. No. 11,111,313

ANTI-PCSK9 ANTIBODIES

WUXI BIOLOGICS IRELAND LI...


1. An isolated antibody or an antigen binding fragment thereof, comprising: a heavy chain variable region comprising an HCDR1 comprising SEQ ID NO: 13, an HCDR2 comprising SEQ ID NO: 15, and an HCDR3 comprising SEQ ID NO: 17; and a light chain variable region comprising an LCDR1 comprising SEQ ID NO: 19, an LCDR2 comprising SEQ ID NO: 21, and an LCDR3 comprising SEQ ID NO: 23, wherein the isolated antibody or an antigen binding fragment thereof specifically binds to Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9).
US Pat. No. 11,111,314

NON-HUMAN ANIMALS THAT SELECT FOR LIGHT CHAIN VARIABLE REGIONS THAT BIND ANTIGEN

Regeneron Pharmaceuticals...


1. A mouse comprising in its germline genome:(i) at an endogenous immunoglobulin (Ig) heavy chain locus, an unrearranged human Ig light chain variable kappa (V?) gene segment and an unrearranged human Ig light chain joining kappa (J?) gene segment operably linked to an endogenous Ig heavy chain constant region nucleic acid sequence comprising at least one intact Ig heavy chain constant region gene encoding a functional CH1 domain, wherein the at least one intact Ig heavy chain constant region gene is an Ig? gene, Ig? gene, Ig? gene, Ig? gene or an Ig? gene, wherein the unrearranged human Ig V? gene segment and the unrearranged human Ig J? gene segment rearrange in a B cell to form a hybrid sequence comprising a rearranged human Ig V?/J? gene sequence operably linked to the endogenous Ig heavy ? chain constant region nucleic acid sequence;
(ii) at an endogenous Ig light chain ? locus, a human universal Ig light chain variable region nucleotide sequence comprising a single human Ig V? gene segment rearranged with a single human Ig J? gene segment operably linked to an endogenous Ig light chain ? constant region nucleic acid sequence;
wherein the mouse expresses an antigen-binding protein that comprises a human Ig hybrid chain derived from the rearranged human Ig V?/J? gene sequence operably linked to the endogenous Ig heavy chain constant region nucleic acid sequence and a cognate light chain derived from the human universal Ig light chain variable region nucleotide sequence at the endogenous Ig light chain locus, wherein the human Ig hybrid chain comprises a human Ig light chain variable ? (hV?/CHxULC) domain fused to an endogenous heavy chain constant IgM, IgD, IgG, IgE or IgA region comprising a functional CH1 domain, and wherein the cognate light chain comprises a human Ig light variable ? domain chain fused to an endogenous light chain ? constant domain.

US Pat. No. 11,111,315

HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS

Xencor, Inc., Monrovia, ...


1. A composition comprising an CD123 antigen binding domain comprising:a) a variable heavy domain comprising a vhCDR1 having SEQ ID NO:440, vhCDR2 having SEQ ID NO:441 and a vhCDR3 having SEQ ID NO:442; and
b) a variable light domain comprising a v1CDR1 having SEQ ID NO:444, v1CDR2 having SEQ ID NO:445 and a v1CDR3 having SEQ ID NO:446.

US Pat. No. 11,111,316

CHITOSAN-DERIVED COMPOSITIONS

IMMUNOPHOTONICS, INC., S...


1. A pharmaceutical formulation comprising a glycated chitosan having a molecular weight of about 100,000 to about 300,000 Daltons; wherein the glycated chitosan has a degree of deacetylation of about 75% to about 99% and a degree of glycation of free amino groups of about 0.1% to about 30%; and further wherein the pharmaceutical formulation is a sterile aqueous solution formulated for injection, and further wherein either:the glycated chitosan has a molecular weight of about 250,000 Daltons; or
the glycated chitosan has a degree of glycation of about 2-7% or about 12.5%.

US Pat. No. 11,111,317

CORDYCEPS MILITARIS MEDIUM POLYSACCHARIDE, METHOD FOR SEPARATING AND PURIFYING SAME, AND USE THEREOF

SOUTH CHINA NORMAL UNIVER...


1. A method for separation and purification of a Cordyceps militaris medium polysaccharide, comprising the following steps:(1) extraction of the Cordyceps militaris medium polysaccharide: drying the Cordyceps militaris rice medium leftovers, pulverizing and sieving same to obtain a dry powder of the leftovers; weighing the dry powder and adding 15-16 times distilled water by mass into same, performing an ultrasonic treatment for at least 30 min, performing a reflux extraction at 70° C. for 1.5 h-2.0 h, pooling the extract solutions after several extractions, and filtering the pooled extract and concentrating same to obtain a polysaccharide concentrate; adding 3-4 times of 95% (V/V) ethanol by volume into the polysaccharide concentrate, stirring same, and allowing same to stand overnight at 4° C.; after centrifugation, drying the precipitate to obtain a Cordyceps militaris medium polysaccharide extract;
(2) decoloration of the Cordyceps militaris medium polysaccharide: dissolving the Cordyceps militaris medium polysaccharide extract by adding distilled water, adjusting the pH value to 8.0-8.5, adding H2O2 solution dropwisely until colorless, and maintaining the temperature at 50° C.-55° C. for at least 2 h;
(3) deproteinization by an enzymatic method combined with Sevage method:
3-1: mixing a papain solution with the Cordyceps militaris medium polysaccharide extract solution, wherein the volume ratio of the two is 1.0:1.5-1.0:1.7, and performing an enzymolysis at 60° C.-70° C. for 2 h-3 h;
3-2: mixing a Sevage reagent with the solution obtained by the enzymolysis at a volume ratio of 1:5, culturing same with shaking for at least 30 min, then centrifuging for multiple times until no protein is precipitated out; and drying the supernatant to obtain a crude Cordyceps militaris medium polysaccharide;
(4) separation and purification of the Cordyceps militaris medium polysaccharide: dissolving the crude Cordyceps militaris medium polysaccharide with distilled water, then loading same to DEAE agarose gel FF ion exchange chromatography column, and eluting same with distilled water to obtain the polysaccharide.

US Pat. No. 11,111,575

PVD VACUUM PLATING PROCESS FOR ALUMINUM ALLOY SURFACE

Foshan Nanhai Jingdingtai...


1. A PVD vacuum plating process for an aluminum alloy surface, comprising:forming a bottom layer by utilizing an arc power supply, with a bias voltage being controlled at 200-300 V, and a time being controlled at 3-5 minutes;
forming an intermediate multi-layer with an oxide and a nitride, with a number of layers being controlled at 8-10, a time for forming an individual layer being controlled at 10-20 minutes, and a target current being controlled at 10-20 A;
forming a transitional engagement layer by conducting mixed sputtering of a transition layer and a color layer for a time of 15-25 minutes;
forming a layer consisting of the color layer by controlling a time for forming the layer consisting of the color layer at 20-30 minutes; and
forming a protective layer by using a power supply with a time controlled at 40-50 minutes, so as to obtain a PVD layer as the protective layer.

US Pat. No. 11,111,319

POLYVINYL ALCOHOL

KURARAY CO., LTD., Kuras...


1. A polyvinyl alcohol consisting of vinyl alcohol units and vinyl ester units; whereina number-average molecular weight (Mn) of the polyvinyl alcohol is from 4,400 to 220,000,
a molecular weight distribution (Mw/Mn) of the polyvinyl alcohol is from 1.05 to 1.70,
a content of vinyl alcohol units of the polyvinyl alcohol is from 80 to 99.99 mol %, and
a carbon-carbon double bond content (X) of the polyvinyl alcohol is 0.1 mol % or less based on total monomer units, and satisfying a formula;X·Mn?1000??(1).


US Pat. No. 11,109,523

PRECISION CROP PRODUCTION-FUNCTION MODELS

The Regents of the Univer...


1. A computer-implemented method for improving plant production comprising:receiving nutrient data and yield data for a plurality of plants, the nutrient data including concentration levels of one or more nutrient elements in plant tissues;
categorizing the plurality of plants into a plurality of yield categories based on the yield data;
for each yield category of the plurality of yield categories:analyzing the nutrient data and the yield data for plants in the yield category to determine a relationship between a plant yield and a nutrient concentration level for each nutrient element of the one or more nutrient elements; and

for each yield category of the plurality of yield categories:applying fertilizers to the plants in the yield category, the applied fertilizers having a nutrient level for each nutrient element of the one or more nutrient elements, and the nutrient level determined using the determined relationship between the plant yield and the nutrient concentration level for each nutrient element of the one or more nutrient elements for improved yields.


US Pat. No. 11,111,578

ATOMIC LAYER DEPOSITION OF FLUORIDE THIN FILMS

UChicago Argonne, LLC, C...


1. A method of forming a secondary electron emissive coating comprising:providing a substrate within an atomic layer deposition reactor; and
depositing a coating of CaF2 by an atomic layer deposition process including at least one cycle of:pulsing a first metal precursor comprising an alkaline metal amidinate into the reactor for a first metal precursor pulse time;
purging the reactor of the first metal precursor;
pulsing a second precursor comprising a fluorinated compound into the reactor for a second precursor pulse time; and
purging the reactor of the co-reactant precursor;

wherein the depositing occurs at a reaction temperature greater than a highest sublimation temperature of the first metal precursor and the second metal precursor and less than 50° C. above the highest sublimation temperature.

US Pat. No. 11,111,323

HOMOPOLYPROPYLENE RESIN FOR NON-WOVEN FABRIC AND METHOD FOR PREPARING THE SAME

LG Chem, Ltd.


1. A homopolypropylene resin for non-woven fabric, wherein the homopolypropylene resin has tacticity of 80% to 90%, molecular weight distribution of 2.4 or less, melt index of 20 g/10 min to 30 g/10 min, melting point of 145° C. or less, and residual stress rate of 0.05% or less.
US Pat. No. 11,110,040

COMPOSITIONS CONTAINING PLANT MUCILAGE


1. A method of lubricating or moisturizing a bodily tissue comprising:preparing a formulation comprising:a mucilage extracted from Abelmoschus, wherein said mucilage is present in the formulation at a concentration of 0.001%-5.0% (w/v);
one or more emollients, wherein said emollients are selected from the group consisting of Aloe barbadensis leaf juice and glycerin;
one or more antioxidants, wherein said antioxidants are selected from the group consisting of Rubus idaeus seed oil and Citrus unshiu peel extract;

applying the formulation to the bodily tissue selected from the group comprising external tissues and mucosal tissues.

US Pat. No. 11,111,325

POLYMERIZATION PROCESSES

ExxonMobil Chemical Paten...


1. A polymerization process to produce a polyethylene polymer, the process comprising contacting a catalyst system comprising a product of a combination of one or more metallocene catalysts, at least one activator, and at least one support, with ethylene and one or more C3-C10 alpha-olefin comonomers under polymerizable conditions including a temperature range of from 10° C. to 75° C., to produce the polyethylene polymer;wherein the polyethylene polymer has a broad orthogonal composition distribution (BOCD) and furthermore has a density of from 0.890 g/cm3 to 0.950 g/cm3, and
further wherein the one or more metallocene catalysts comprises:(A) a compound represented by Formula (I):TyCpmM6GnX5q??(I),


wherein each Cp is, independently, a cyclopentadienyl group which may be substituted or unsubstituted, M6 is a Group 4 transition metal, G is a heteroatom group represented by the Formula JR*z where J is N, and R* is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, cyclooctyl, cyclododecyl, decyl, undecyl, dodecyl, adamantyl or an isomer thereof and z is 1 or 2, T is a bridging group, and y is 1, X5 is a leaving group, and m=1, n=1, q=0, 1, 2 or 3, and the sum of m+n+q is equal to the oxidation state of the transition metal; and/or(B) one or more of the following compounds:

dimethylsilyl (tetramethylcyclopentadienyl)(cyclododecylamido)titanium dimethyl;
dimethylsilyl (tetramethylcyclopentadienyl)(cyclododecylamido)titanium dichloride;
dimethylsilyl (tetramethylcyclopentadienyl)(t-butylamido)titanium dimethyl; dimethylsilyl (tetramethylcyclopentadienyl)(t-butylamido)titanium dichloride; ?-(CH3)2Si(cyclopentadienyl)(1-adamantylamido)M7(R15)2; ?-(CH3)2Si(3-tertbutylcyclopentadienyl)(1-adamantylamido)M7(R15)2; ?-(CH3)2C(tetramethylcyclopentadienyl)(1-adamantylamido)M7(R15)2; ?-(CH3)2Si(tetramethylcyclopentadienyl)(1-adamantylamido)M7(R15)2; ?-(CH3)2C(tetramethylcyclopentadienyl)(1-tertbutylamido)M7(R15)2; ?-(CH3)2Si(tetramethylcyclopentadienyl)(1-tertbutylamido)M7(R15)2; ?-(CH3)2Si(fluorenyl)(1-tertbutylamido)M7(R15)2; ?-(CH3)2Si(tetramethylcyclopentadienyl)(1-cyclododecylamido)M7(R15)2; or
?-(C6H5)2C(tetramethylcyclopentadienyl)(1-cyclododecylamido)M7(R15)2,
where M7 is selected from a group consisting of Ti, Zr, and Hf and R15 is selected from halogen or C1-C5 alkyl.

US Pat. No. 11,110,041

PROCESS FOR PERMANENT SHAPING HAIR

KAO GERMANY GMBH, Darmst...


1. A process for permanent shaping hair, the process comprising:a—optionally washing hair with a cleansing composition and towel drying the hair;
b—mixing a composition A and a composition B immediately before application onto the hair at a weight ratio of composition A to composition B in the range of 10:0.1 to 10:1 to obtain a ready-to-use composition having an alkaline pH in the range from 7.3 to 11;
c—applying the obtained ready-to-use composition onto the hair, and leaving the applied ready-to-use composition on the hair for 1 to 45 min;
d—optionally rinsing the applied ready-to-use composition off the hair with water;
e—optionally applying, onto the hair, an intermediate treatment composition comprising one or more inorganic salts and having a pH from 2 to 7;
f—applying, onto the hair, a fixing composition comprising one or more oxidizing agents and having a pH in the range of 1.5 to 5 and leaving the applied fixing composition on the hair for 1 to 15 min;
g—optionally rinsing the applied fixing composition off the hair; and
h—optionally drying the hair,
wherein
the composition A is an aqueous composition comprising one or more reducing agents, one or more alkalizing agents, and has a pH in the range of 7.5 to 12,
the composition B comprises;i) one or more carboxylic acids having three or more carboxyl groups and/or their salts; and
ii) one or more additional organic acids and/or their salts having one or two carboxyl groups,

the composition B comprises the acids of i) and ii) and/or their salts at a total concentration from 10% to 100% by weight, based on a total of the composition B,
the obtained ready-to-use composition comprises the acids of i) and ii) and/or their salts at a total concentration in the range of 1% to 10% by weight, based on a total of the obtained ready-to-use composition,
the composition B comprises the acids of (i) and (ii) at a weight ratio (i)/(ii) ranging from 10:1 to 1:250,
the hair is put under tension before, during, or after application of the obtained ready-to-use composition, and
the tension is released from the hair before or during application of the fixing composition or prior to rinsing off the applied fixing composition off the hair.

US Pat. No. 11,111,326

HIGHLY FLUORINATED ELASTOMERS

3M Innovative Properties ...


1. A curable composition comprising a curing system, wherein the curing system consists of a highly fluorinated polymer, a peroxide and coagent, and wherein the highly fluorinated polymer is derived from:(a) at least 50 mol % to no more than 65 mol % of tetrafluoroethylene monomer based on total moles of monomer incorporated;
(b) more than 35 mol % to less than 50 mol % of perfluoro (methyl vinyl) ether; and
(c) 0.01 to 1 mol % of Formula III based on total moles of monomer incorporated where Formula (III) is:CF2?CF—(CF2)g—(O—CF(CF3)—CF2)h—O—(CF2)i—(O)j—(CF2)k—CF(I)—X??(III)

wherein X is selected from F or CF3; g is 0; h is 0 i is an integer selected from 1-5; j is an integer selected from 0 or 1; and k is an integer selected from 0-6, wherein at least 95% of the C—H bonds in the backbone of the highly fluorinated polymer are replaced by C—F or C—I bonds.

US Pat. No. 11,110,042

METHODS FOR SYNTHESIZING STANNOUS PYROPHOSPHATE

Colgate-Palmolive Company...


1. A method of making an oral care composition comprising stannous pyrophosphate, comprising the steps of (1) reacting stannous chloride with a tetrasodium pyrophosphate (TSPP) in a water or water/alcohol solvent mixture in a reactor tank, (2) precipitating the stannous pyrophosphate product, optionally (3) recovering the stannous pyrophosphate product by filtration, optionally (4) freeze-drying the stannous pyrophosphate product, and (5) transferring the stannous pyrophosphate product into a mixing tank containing at least one oral care ingredient and at least one orally acceptable solvent.
US Pat. No. 11,111,327

CAST-MOLDING PROCESS FOR PRODUCING UV-ABSORBING CONTACT LENSES

Alcon Inc., Fribourg (CH...


1. A lens-forming composition, comprising:(a) at least one lens-forming material,
(b) at least one photoinitiator,
(c) at least one thiol-containing compound or polymer in an amount for reducing the curing time of the lens-forming composition, with a light having a wavelength from about 380 to about 460 nm, compared to a control composition which differs from the lens-forming composition only in that the control composition is free of any chain-transfer agent while the lens-forming composition comprises said at least one thiol-containing compound or polymer,
(d) at least one metal ion scavenger,
(e) at least one free radical scavenger, and
(f) optionally at least one polymerizable UV-absorbing component having at least one UV-absorbing moiety which absorbs UV radiation having a wavelength of from 200 nm to 400 nm,wherein the lens-forming composition has a pH of from about 2.5 to about 5 and a shelf life of at least 3 days.


US Pat. No. 11,110,044

SKINCARE TREATMENT


1. A method of treating acne comprising:topically administering an acne treating composition to an area of skin exhibiting symptoms of acne, the acne treating composition comprising an acne active ingredient in the presence of an anhydrous composition, wherein the acne active ingredient is selected from the group comprising tretinoin, adapalene, tazarotene, clindamycin, erythromycin, azelaic acid, benzoyl peroxide, hydrogen peroxide and salicylic acid; and
topically administering an aqueous composition to the area of skin,
wherein the anhydrous composition further comprises a component that generates heat on the area of skin in the presence of water, said component is selected from the group consisting of magnesium chloride, iron chloride, zinc chloride, magnesium oxide, calcium oxide, magnesium sulphate and calcium chloride.

US Pat. No. 11,110,045

ORAL COMPOSITIONS

Michael Arnold, Beverly ...


1. A chewable composition for teeth-whitening, comprisingan anhydrous chewing gum base having water content of about 1% or less,
an anhydrous fruit acid,
carbamide peroxide having water content of about 2% or less, and
one or more gum additives,
wherein, the ratio of gum base:carbamide peroxide:fruit acid, in percent weight relative to the composition, is about 10-50:1-20:0.5-8, and the one or more gum additives are present in an amount sufficient to reach 100% of the weight of the composition.

US Pat. No. 11,111,330

SYNTHESIS OF MULTIPHASE SELF-HEALING POLYMERS FROM COMMODITY MONOMERS

The Regents of the Univer...


1. A self-healing polymer material comprising a multiphase copolymer comprising one or more hydrogen bond-forming copolymer segments, each hydrogen bond-forming copolymer segment comprising a polymerized acrylamide monomer and a polymerized acrylic monomer, the polymerized acrylic monomer being a methacrylate monomer or an acrylate monomer, or a combination thereof,wherein the polymerized acrylamide monomer comprises functional groups that form hydrogen bonds in the multiphase copolymer, and wherein the multiphase copolymer further comprises polymerized styrenic segments forming glassy domains in the multiphase copolymer.

US Pat. No. 11,114,689

SOLID ELECTROLYTE COMPOSITION, SOLID ELECTROLYTE-CONTAINING SHEET, ALL-SOLID STATE SECONDARY BATTERY, AND METHODS FOR MANUFACTURING SOLID ELECTROLYTE-CONTAINING SHEET AND ALL-SOLID STATE SECONDARY BATTERY

FUJIFILM Corporation, To...


1. A solid electrolyte composition comprising:(A) a sulfide-based inorganic solid electrolyte having a conductivity of an ion of a metal belonging to Group I or II of the periodic table;
(B) an active material having a surface coated with an oxide having an ion conductivity; and
(C) a dispersion medium,
wherein the dispersion medium (C) includes a polar dispersion medium (C1) satisfying the following conditions 1 and 2,

the polar dispersion medium has at least one polar group selected from the following group of polar groups,

a hydroxy group, an ether group, an amino group, an amide group, an ester group, a carbonyl group, a carbonate group, a carboxy group, and a cyano group, and

at least one of substituents that are bonded to the polar group is a hydrocarbon group having a branched structure.